NYSE:NVRO Nevro Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nevro Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $143.90 -0.53 (-0.37 %) (As of 09/23/2020 02:04 PM ET) Add Compare Share Today's Range$142.62Now: $143.90▼$145.4450-Day Range$130.41MA: $137.60▼$145.5152-Week Range$65.05Now: $143.90▼$148.63Volume4,730 shsAverage Volume431,963 shsMarket Capitalization$4.94 billionP/E RatioN/ADividend YieldN/ABeta0.87 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingNevro has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $142.18, Nevro has a forecasted downside of 2.1% from its current price of $145.28.Amount of Analyst CoverageNevro has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesNevro has received 455 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNevro has received 316 “underperform” votes. (Add your “underperform” vote.)Community SentimentNevro has received 59.01% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote “Outperform” if you believe NVRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,022,071.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Nevro is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nevro are expected to grow in the coming year, from ($2.95) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is -48.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is -48.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNevro has a P/B Ratio of 20.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVRO Previous Symbol CUSIPN/A CIK1444380 Webwww.nevro.com Phone650-251-0005Debt Debt-to-Equity Ratio0.37 Current Ratio3.25 Quick Ratio2.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$390.26 million Price / Sales12.65 Cash FlowN/A Price / Cash FlowN/A Book Value$6.98 per share Price / Book20.62Profitability EPS (Most Recent Fiscal Year)($3.37) Net Income$-103,690,000.00 Net Margins-27.22% Return on Equity-38.86% Return on Assets-18.31%Miscellaneous Employees804 Outstanding Shares34,313,000Market Cap$4.94 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $143.90 -0.53 (-0.37 %) (As of 09/23/2020 02:04 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NVRO News and Ratings via Email Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter. Nevro (NYSE:NVRO) Frequently Asked Questions How has Nevro's stock price been impacted by Coronavirus (COVID-19)? Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 31.0% and is now trading at $143.90. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Nevro? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nevro. When is Nevro's next earnings date? Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Nevro. How were Nevro's earnings last quarter? Nevro Corp (NYSE:NVRO) issued its quarterly earnings results on Wednesday, August, 5th. The medical equipment provider reported ($1.21) EPS for the quarter, topping analysts' consensus estimates of ($1.65) by $0.44. The medical equipment provider had revenue of $56.39 million for the quarter, compared to analyst estimates of $41.46 million. Nevro had a negative net margin of 27.22% and a negative return on equity of 38.86%. View Nevro's earnings history. What price target have analysts set for NVRO? 11 Wall Street analysts have issued 12 month price targets for Nevro's shares. Their forecasts range from $100.00 to $165.00. On average, they expect Nevro's stock price to reach $142.18 in the next twelve months. This suggests that the stock has a possible downside of 1.2%. View analysts' price targets for Nevro. Who are some of Nevro's key competitors? Some companies that are related to Nevro include Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Inspire Medical Systems (INSP), Inari Medical (NARI) and Inovio Pharmaceuticals (INO). View all competitors. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), General Electric (GE), Gilead Sciences (GILD), Adobe (ADBE), Advanced Micro Devices (AMD), Walt Disney (DIS) and Starbucks (SBUX). Who are Nevro's key executives? Nevro's management team includes the following people: Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)Mr. Patrick Schmitz, VP of Operations (Age 59)Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)Mr. Doug Alleavitch, VP of Quality (Age 58)Mr. D. Keith Grossman, Pres, CEO & Director (Age 59) What is Nevro's stock symbol? Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO." Who are Nevro's major shareholders? Nevro's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.91%), Jackson Square Partners LLC (3.11%), ArrowMark Colorado Holdings LLC (1.24%), Victory Capital Management Inc. (1.19%), Nuveen Asset Management LLC (1.10%) and Holocene Advisors LP (0.94%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick. View institutional ownership trends for Nevro. Which major investors are selling Nevro stock? NVRO stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Two Sigma Advisers LP, ClariVest Asset Management LLC, Robeco Institutional Asset Management B.V., Mackay Shields LLC, Canada Pension Plan Investment Board, SG Americas Securities LLC, and HighTower Advisors LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick. View insider buying and selling activity for Nevro. Which major investors are buying Nevro stock? NVRO stock was bought by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Vanguard Group Inc., Thrivent Financial for Lutherans, Jennison Associates LLC, Nuveen Asset Management LLC, Balyasny Asset Management LLC, Holocene Advisors LP, and Goldman Sachs Group Inc.. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle. View insider buying and selling activity for Nevro. How do I buy shares of Nevro? Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nevro's stock price today? One share of NVRO stock can currently be purchased for approximately $143.90. How big of a company is Nevro? Nevro has a market capitalization of $4.94 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe. What is Nevro's official website? The official website for Nevro is www.nevro.com. How can I contact Nevro? Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
